Antibiotics

In the latest column from SIDP, handshake stewardship prioritizes face-to-face communication between frontline providers to enable feedback to assess the appropriateness of prescribed antimicrobials.

The 2019 Strategic Plan of the Infectious Diseases Society of America lays the groundwork for understanding prescribing practices.

Latest update of the bill introduced in the House November, but no word on a potential vote yet.

Shorter durations of antibiotic therapy demonstrate similar efficacy and may improve safety compared with longer courses for certain infections.

Investigators examined the efficacy and safety of carbapenems vs select novel antibiotics for treatment of cUTI.

This nitroimidazole antibiotic is shown to be efficacious for this condition.

To reduce antimicrobial resistant pathogens, nursing homes should carefully monitor their use of hospital-grade antibiotics.

A process known as thin film freezing can convert existing therapies into powder that offers another delivery solution and may help alleviate storage challenges in developing countries.

While Clostridioides difficile infection (CDI) risk appeared to drop, investigators said the overall risk of infection among patients was not changed in a statistically significant way.

Hospitals with lower c difficile antibiotic usage averaged shorter length-of-stay than hospitals that prescribed more antibiotics.

More than 1.2 million people were estimated to have died in 2019 as a direct result, and that antimicrobial-resistant infections played a role in millions more.

In the latest column from SIDP, the authors discuss having leaders to help navigate school and beyond.

Matt Henn, chief scientific officer at Seres Therapeutics, discusses new ways of targeting infectious diseases and antimicrobial resistant infections.

Antimicrobial resistance is “the silent pandemic,” Dr. Leonard Friedland says, and vaccines are how we fight it.

The website, LearnAntibiotics.com, is a supplemental tool offering guides, practice exams, and other resources to help students, residents, or practicing professionals with infectious diseases pharmacotherapy.

The federal agency will provide $22 million in funding to organizations worldwide dedicated to identifying next crisis.

Recent study results show promising new modalities.

Neonatal vancomycin trial found loading with more frequent dosing over shorter time comparable to standard regimen but adversely affected hearing.

The Infectious Diseases Society of America (IDSA) released new expert-informed guidelines for treating antimicrobial-resistant AmpC β-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia infections.

The report on antimicrobial resistance finds new therapeutics are "essential to future of clinical medicine" but may not be viable in present market.

As providers were challenged to care for patients with severe COVID-19 In the first year of the pandemic, antibiotic usage increased. Listen to clinicians talk about this specific challenge and how prescribing practices evolved over time.

The report assesses progress of a US national action plan to combat antimicrobial resistance, called for by 2015 World Health Assembly.

From its origins as a serendipitous discovery to being successfully prescribed for nearly a century, antibiotics remain a foundation of medicine. However it has major ongoing challenges including the rise of superbugs and the development of antimicrobial resistance (AMR). There are some prospective strategies to combat AMR on the horizon.

Providers and key stakeholders weigh in on this significant topic.

The European Center for Diseases Prevention and Control published data today showing the greatest decrease in antibiotic consumption in 2 decades coincided with the COVID-19 pandemic.

In the second installment discussing this report, the authors point out that the approval of new diagnostics can help facilitate better stewardship.

The National Academies report reviews several challenges, and ways to overcome them for optimal antimicrobial stewardship.

CEO Christopher Burns spoke about their investigational therapy pipeline, the long view perspective for the company, and how the federal government’s use of the nomenclature innovation might actually hinder incremental improvements in antibiotic development.